Aquestive Therapeutics, Inc. — Operating Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/68798aeb-5350-4609-aaca-ee4d37d9c447/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-71.1M | 2025-01-01 – 2025-12-31 | evidence 0001398733-26-000018 |
| FY 2024 | $-30.8M | 2024-01-01 – 2024-12-31 | evidence 0001628280-25-010506 |
| FY 2023 | $-15.1M | 2023-01-01 – 2023-12-31 | evidence 0001628280-24-009010 |
| FY 2022 | $-42.1M | 2022-01-01 – 2022-12-31 | evidence 0001628280-23-010180 |
| FY 2021 | $-34.7M | 2021-01-01 – 2021-12-31 | evidence 0001628280-22-005393 |
| FY 2020 | $-42.9M | 2020-01-01 – 2020-12-31 | evidence 0001140361-21-007811 |
| FY 2019 | $-52.7M | 2019-01-01 – 2019-12-31 | evidence 0001140361-20-005499 |
| FY 2018 | $-48.9M | 2018-01-01 – 2018-12-31 | evidence 0001140361-19-004934 |
| FY 2017 | $-113.0k | 2017-01-01 – 2017-12-31 | evidence 0001140361-19-004934 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Aquestive Therapeutics, Inc. — all facts · Revenue · Net Income